Opinion: Why negotiating drug prices won’t hinder new cures

Argentina Noticias Noticias

Opinion: Why negotiating drug prices won’t hinder new cures
Argentina Últimas Noticias,Argentina Titulares
  • 📰 mercnews
  • ⏱ Reading Time:
  • 63 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 28%
  • Publisher: 68%

Public investments contribute substantively to the emergence of new drugs and drug-related patents.

Big Pharma is pulling out all the stops to avoid lowering drug prices for seniors.

The pharmaceutical industry has argued that negotiating Medicare prices with the federal government will force them to pull back on developing groundbreaking new treatments. As Eli Lilly CEO David Ricks said in an interview this summer with CNBC, “I’m really worried about the harm this will do to new cures and possibilities in medicine.”

Amazingly, given the pervasiveness of the industry’s argument, a recent study found that NIH funding contributed to nearly all of FDA-approved drugs from 2010 to 2019, and the magnitude of NIH investment in new drugs is comparable with that of the industry. These findings clearly suggest that the public deserves a more equitable return on its investment relative to the pharmaceutical industry’s investment.

The public’s misunderstanding about the role of government in health care is not an accident. The scope of public funding is intentionally hidden from the American public. First, and not unexpectedly, most companies actively hide the subsidies they accept from government . Pfizer, for example, misleadingly claims it did not receive any government research funding to develop its COVID-19 vaccine, but its partner, BioNTech, was founded based on the NIH-funded mRNA discovery.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

mercnews /  🏆 88. in US

Argentina Últimas Noticias, Argentina Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

OPINION: Alaskans should be dubious of Dunleavy’s plan to use public money to defend himselfOPINION: Alaskans should be dubious of Dunleavy’s plan to use public money to defend himselfGiven the well-documented legal opinions and public testimony opposing this idea, why are the governor and attorney general attempting to bring back this plan?
Leer más »

Opinion: Why a G20 without Putin and Xi could be a fantastic opportunityOpinion: Why a G20 without Putin and Xi could be a fantastic opportunityWith both Russian President Vladimir Putin and Chinese President Xi Jinping skipping the upcoming G20 meeting in New Delhi, “this could be an opportunity for greater unity on key issues for those world leaders still attending,” writes David A. Andelman.
Leer más »

Frumpy Mom: Why smoking in public is a gamble some are willing to takeFrumpy Mom: Why smoking in public is a gamble some are willing to takeIt’s always amazing to me when I walk into one of these fabulous establishments and it smells like mountains of unwashed socks.
Leer más »

Why I went back to the iPhone 14 Pro Max (and why I still love it)Why I went back to the iPhone 14 Pro Max (and why I still love it)Earlier this year, I stopped using the iPhone 14 Pro Max because of its size and weight. But I recently went back to it, and something interesting happened.
Leer más »

Random! Bill Maher thinks writers aren’t “owed a living”Random! Bill Maher thinks writers aren’t “owed a living”Is this opinion from Bill Maher worthy of a place called 'Club Random”
Leer más »



Render Time: 2025-03-10 21:54:34